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SFTI-1 is a small cyclic peptide from sunflower seeds that is
one of themost potent trypsin inhibitors of any naturally occur-
ring peptide and is related to the Bowman-Birk family of inhib-
itors (BBIs). BBIs are involved in the defense mechanisms of
plants and also have potential as cancer chemopreventive
agents. At only 14 amino acids in size, SFTI-1 is thought to be a
highly optimized scaffold of the BBI active site region, and thus
it is of interest to examine its important structural and func-
tional features. In this study, a suite of 12 alanine mutants of
SFTI-1 has been synthesized, and their structures and activities
have been determined. SFTI-1 incorporates a binding loop that
is clasped together with a disulfide bond and a secondary pep-
tide loop making up the circular backbone. We show here that
the secondary loop stabilizes the binding loop to the conse-
quences of sequence variations. In particular, full-length BBIs
have a conserved cis-proline that has been shown previously to
be required forwell defined structure andpotent activity, butwe
show here that the SFTI-1 scaffold can accommodate mutation
of this residue and still have a well defined native-like confor-
mation and nanomolar activity in inhibiting trypsin. Among the
Ala mutants, the most significant structural perturbation
occurred when Asp14 was mutated, and it appears that this res-
idue is important in stabilizing the transpeptidebondpreceding
Pro13 and is thus a key residue in maintaining the highly con-
strained structure of SFTI-1. This aspartic acid residue is
thought to be involved in the cyclization mechanism associated
with excision of SFTI-1 from its 58-amino acid precursor. Over-
all, this mutational analysis of SFTI-1 clearly defines the opti-
mized nature of the SFTI-1 scaffold and demonstrates the
importance of the secondary loop inmaintaining the active con-
formation of the binding loop.
Protease inhibitors are of significant interest because they
play key roles in an extremely wide range of physiological func-
tion, including peptide hormone release, blood coagulation,
and complement fixation. They have also been implicated in
the treatment of various diseases, including some cancers and
inflammatory processes (1). Bowman-Birk inhibitors (BBIs),3
one of at least 18 different families of serine protease inhibitors,
are involved in plant defense and have been implicated as can-
cer chemopreventive agents (2). The focus of this paper is
SFTI-1 (sunflower trypsin inhibitor 1), a 14-residue cyclic pep-
tide isolated from sunflower seeds that is related to the Bow-
man-Birk inhibitors and is one of the most potent inhibitors of
trypsin of any naturally occurring peptide (3). SFTI-1 forms a
tightly folded scaffold, either when complexed with trypsin or
free in solution (3, 4). Its compact structure (shown in Fig. 1)
and high potency have led to suggestions that it may serve as a
scaffold for the design of novel peptide-based drug leads (5).
The structure of SFTI-1 consists of two -strands connected
at each end by turns and is braced by a single disulfide bond that
creates two distinct loops (3, 4).One loop, known as the binding
loop, contains the reactive site sequence Lys5–Ser6, although
the “secondary” loop contains a -hairpin turn that essentially
cyclizes the binding loop. SFTI-1 inhibits trypsinwith aKi of 0.1
nM (3) and inhibits cathepsin Gwith a comparableKi. SFTI-1 is
highly selective as it is 74-fold less inhibitory for chymotrypsin,
and 3 orders of magnitude less inhibitory for elastase and
thrombin. It has no detectable inhibitory activity against factor
Xa (3).
Although SFTI-1 is only 14 residues in size, it has remarkable
similarity to the active site sequence of the Bowman-Birk tryp-
sin inhibitors that are typically 60–90 amino acids in length.
Three key features have been identified that are conserved
betweenBBIs and SFTI-1, namely covalent cyclization of a hair-
pin loop via a disulfide bridge, a cis-Pro at the P3-site (using the
protease active site nomenclature of Schechter and Berger (6)),
and an extensive network of hydrogen bonds. The active site
sequences of selected BBIs are given in Fig. 2 to highlight some
of these features. A range of synthetic peptides based on the
BBIs have been synthesized and their activities determined, as
reviewedbyKorsinczky et al. (7). Essentially all of the important
features identified from these studies appear to have been
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incorporated naturally into the SFTI framework, demonstrat-
ing that native SFTI is a highly optimized trypsin inhibitory
scaffold.
The precursor protein of SFTI-1 was recently discovered,
and the sequence is given in Fig. 1. Interestingly, the sequence of
the precursor does not show any similarities with the Bowman-
Birk inhibitors, apart from the mature peptide domain, posing
questions about the evolution of SFTI-1 (8). Themechanism of
cyclization has yet to be elucidated, and the presence of a GR
dipeptide motif at both ends of the mature sequence leaves a
degree of ambiguity as to the cleavage sites (8), although it is
likely that cyclization occurs between an Asp and a Gly residue
(see Fig. 1), which opens up the possibility of a role for an aspar-
aginyl endoprotease in the process (8). Themechanismof cycli-
zation of the largest family of backbone cyclic proteins, the
plant cyclotides (9), has also been suggested to involve an Asp/
Asn-Gly and may also involve an asparaginyl endoprotease,
although this has yet to be experimentally verified (10). Circular
proteins have also been reported in bacteria andmammals, and
the mechanism of cyclization is similarly unknown (11).
As well as having potential applications as a protein engi-
neering scaffold, SFTI-1 also displays potent inhibitory activity
against matriptase, an enzyme implicated in prostate cancer,
suggesting that it may also have direct therapeutic applications
(12–14). Matriptase was first isolated as a novel proteinase
expressed by human breast cancer cells and is also highly
expressed in prostate, breast, and colorectal cancers in vitro and
in vivo (12, 13). Inhibition of matriptase suppresses both pri-
mary tumor growth and metastasis in a rat model of prostate
cancer.
Understanding the structure-activity relationships of SFTI-1
will facilitate potential protein engineering and therapeutic
applications of this peptide. Mutagenesis studies involving the
systematic replacement of individual residues also have the
potential to provide insights into their role in the cyclization
mechanism. In this study we have synthesized a complete suite
of alanine mutants of SFTI-1 and characterized them structur-
ally and functionally. Lys5 is the only residue that resulted in a
significant loss of trypsin inhibitory activity, and most surpris-
ingly, the cis-Pro that is highly conserved across the Bowman-
Birk inhibitors is not critical for activity.
MATERIALS ANDMETHODS
Peptide Synthesis—Boc-based solid phase peptide synthesis
was carried out using standard protocols. Peptides were assem-
bled using a thioester linker assembled on resin allowing sub-
sequent cyclization by a thiazipmechanism (15). Hydrogen flu-
oride cleavage was conducted on the deprotected resins using
standard protocols (0 °C, 90 min, 90% HF, 8% p-cresol, 2%
p-thiocresol). Crude cleavage products were purified by RP C18
HPLC (1%/minute gradient of 90% acetonitrile, 10% water,
0.05% trifluoroacetic acid against 100% water, 0.05% trifluoro-
acetic acid) to give linear, reduced peptides. Peptides were
cyclized and oxidized in 0.1 M ammonium bicarbonate at pH 8
overnight and purified as above. Purity of fractionswas assessed
using electrospray ionization-mass spectrometry and analytical
HPLCusing a 2%/minute gradient of the same solvents used for
previous steps.
NMR Spectroscopy—Samples for 1H NMR measurements
contained 1 mM peptide in 90% H2O, 10% D2O (v/v) at pH
5. D2O (99.9 and 99.99%) was obtained from Cambridge Iso-
tope Laboratories, Woburn, MA. Spectra were recorded at 290
K on a Bruker Avance-500 or Avance-600 spectrometer
equippedwith a shielded gradient unit. Two-dimensionalNMR
spectra were recorded in phase-sensitivemode using time-pro-
portional phase incrementation for quadrature detection in the
t1 dimension (16). The two-dimensional experiments con-
sisted of a TOCSY (17) using an MLEV-17 spin lock
sequence (18) with a mixing time of 80 ms and nuclear Over-
hauser effect spectroscopy (19) with mixing times of 100–
250 ms. Solvent suppression was achieved using a modified
WATERGATE sequence (20). Spectra were acquired over
6024 Hz with 4096 complex data points in F2 and 512 incre-
ments in the F1 dimension. Spectra were processed on a Sil-
icon Graphics Indigo work station using XWINNMR
(Bruker) software. The t1 dimension was zero-filled to 1024
real data points, and 90° phase-shifted sine bell window func-
tions were applied prior to Fourier transformation.
Trypsin Inhibition—The concentrations of the inhibitory
active peptides and the equilibrium dissociation constants Ki
were determined with trypsin. Bovine pancreatic trypsin (N-p-
tosyl-L-phenylalanine chloromethyl ketone-treated; Sigma)
was standardized by burst titration with p-nitrophenyl p-gua-
nidinobenzoate (21). Trypsin (25 nM) was then incubated with
serial dilutions of the peptides in 50 mMHEPES, 150 mMNaCl,
FIGURE 1. Sequence and structure of native SFTI-1 and its precursor pro-
tein. Ribbon representations of the NMR derived three-dimensional struc-
tures of SFTI-1 (4) and prepro-SFTI-1 (8) are shown adjacent to the sequences.
The -strands are shown as arrows. The potential cleavage sites involved in
excision of the mature peptide from the precursor protein are labeled with
arrows.
FIGURE 2. A comparison of the active site sequences of Bowman-Birk
inhibitors with SFTI-1. The conserved cis-proline residue at the P3-position
is highlighted in italics, and the two cysteine residues that are linked in a
disulfide bond to form the binding loop are highlighted in boldface. The
standard Schechter andBerger nomenclature (6) for protease active site posi-
tions is illustrated below the BBI sequences.
Structural Analysis of SFTI-1
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0.01% Triton X-100, 0.01% sodium azide, pH 7.4, for 5 min at
room temperature. The residual activity was quantified by fol-
lowing the hydrolysis of the substrate carbobenzoxy-L-argi-
nine-7-amino-4-methylcoumarin (125 M; Sigma) in an HTS
7000 BioAssay Reader (PerkinElmer Life Sciences). The con-
centrations of the active peptideswere calculated by assuming a
1:1 interaction between inhibitor and trypsin; the mutant K5A
could not be titrated because of its considerably lower affinity,
and HPLC and amino acid analyses were used for quantifica-
tion. Subsequently similar experiments were performed at a
lower enzyme concentration to determine the equilibrium dis-
sociation constant for the complex (22). Thus, the peptides
were incubated with trypsin (0.01 nM), and the residual activity
was quantified using the substrate N-p-tosyl-glycine-proline-
arginine-7-amido-4-methylcoumarin (5 M; Sigma). The Ki
valueswere calculated by fitting the steady state velocities to the
equation for tight binding inhibitors (23) using nonlinear
regression analysis with the software ProFit (Quantum Soft,
Uetikon am See, Switzerland). Mean values  S.D. of at least
four experiments are reported.
RESULTS
Each non-cysteine residue in SFTI-1 was replaced individu-
ally with an alanine residue in a suite of peptides synthesized
using Boc-based solid phase peptide synthesis. The native pep-
tide was also synthesized for comparison. For convenience the
peptides are referred to here by reference to the mutation, e.g.
G1A for [1-Ala]SFTI-1. For a cyclic sequence of n residues,
there are in principle n choices of linear precursors for the syn-
thesis. For the mutants of SFTI-1, the peptide sequences were
assembled with the flanking residues being a C-terminal thio-
ester and anN-terminal cysteine residue to facilitate cyclization
via an adaptation of native peptide ligation chemistry (24, 25).
Fig. 3 outlines the chemical strategy involved. Briefly, nucleo-
philic attack of theN-terminal Cys on the thioester linker at the
C terminus results in a cyclic thiolactam that subsequently rear-
ranges via an S- to N-acyl transfer to produce a native peptide
bond. As there are two cysteine residues in SFTI-1, there are
two possible ligation points. The preferred ligation point was
chosen to be between Cys3 and Arg2, or in the case of R2A
between Cys3 and Ala2.
Formation of the cyclic backbone and disulfide bond was
generally performed in a single step in 0.1 M ammonium
bicarbonate at pH 8. For D14A the cyclization reaction did
not proceed efficiently and a two-step approach was
required. The cyclization reaction was performed in the
presence of TCEP, and following purification of the cyclic
product, the peptide was oxidized in 0.1 M ammonium bicar-
bonate. The TCEPwas used to keep the two cysteine residues
in a reduced state as this appears to facilitate the cyclization
reaction. All peptides were purified using preparative
reverse phase HPLC (RP-HPLC) and characterized using
analytical scale RP-HPLC and mass spectrometry.
Sufficient quantities of the 12 SFTI-1 Ala mutants were iso-
lated and purified for structural analysis with NMR spectros-
copy and functional analysis of the trypsin inhibitory activity.
The NMR spectra were recorded in aqueous solution at 290 K,
and NMR spectral assignments were made using established
techniques (26). Chemical shifts, in particular the H shifts, are
extremely sensitive to structural changes and thus offered a
convenient method of assessing structural changes that may
have occurred upon alanine substitution.
Under the conditions examined, one predominant confor-
mation was present in solution for the native peptide. Analysis
of TOCSY spectra between pH 2.8 and 5.8 indicated that Asp14
has a pKa of4, and there were no significant conformational
changes over this pH range (as assessed via a lack of H chem-
ical shift changes). The SFTI-1 mutants also displayed only one
predominant conformation, with the exception of D14A, for
which two isomers were present. The NMR spectra of the
SFTI-1 mutants were recorded at both pH 4 and 5, which gave
essentially identical spectra, again showing a lack of pH-in-
duced conformational changes. A comparison of the secondary
shifts of native SFTI with the mutants (at pH 5) is shown in Fig.
4. Themajority of themutants display chemical shifts very sim-
ilar to the native peptide, indicating that no major structural
changes occur as a result of the mutations. However, I7A, P8A,
and P9A display differences for certain residues that indicate
local structural perturbations. I7Adiffers at residue 7, but this is
likely to result from a local effect of the alanine substitution.
P8A has changes for residues 6–8, whereas P9A differs at res-
idue 8. T4A also displays minor differences from the native
peptide.
A comparison of the TOCSY spectrum of D14A with native
SFTI-1 is given in Fig. 5. It is clear that one major conformer is
present in native SFTI-1, whereas D14A has two sets of spin
systems from two distinct conformations. For some residues
significant differences are observed for the amide chemical
shifts of the two conformers, and in some cases no differences,
FIGURE3.Aschematic representationof the strategy for synthesizing the
SFTI-1 analogues. A thioester linker is attached to the solid support (resin)
and the peptide chain assembled using Boc chemistry. The peptide with the
linker attached is cleaved from the resin using HF and a single step reaction
used for cyclizing thebackboneandoxidizing thedisulfidebond. Thebinding
and secondary loops of the SFTI-1 sequence are shown in lighter and darker
shading, respectively.
Structural Analysis of SFTI-1
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or only minor differences, are evi-
dent. Assignment of both conform-
ers showed that Pro13 is present in a
trans conformation in one of the
conformers and a cis conformation
in the other. The discrimination of
the trans and cis formswas based on
detection of di-1 and d nuclear
Overhauser effects, respectively, for
the X-Pro peptide bonds. The sec-
ondary shifts (i.e. the differences
between observed and random coil
H chemical shifts) of the non-na-
tive cis conformation of D14A differ
from the native peptide at residues
12–14, in contrast to the trans con-
formation, which is very similar to
the native peptide (Fig. 4). Prolines 8
and 9 are present as cis and trans
forms, respectively, in both con-
formers. Clearly, mutating Asp14 to
an alanine residue has a significant
effect on the stability of the turn
region involving residues 12–14 and
1. (Note that residues 14 and 1 are
sequentially adjacent in the cyclic
peptide.)
Although the geometry of Pro13 is
affected in D14A, the native trans
conformation is maintained in all
other Ala mutants containing this
Asp residue. When present, Pro8
and Pro9 also maintain their native
geometries (i.e. cis for Pro8 and
trans for Pro9) in the Ala mutants.
The ability of SFTI-1 and the ana-
logues to inhibit trypsin was com-
pared by determining the equilib-
rium dissociation constants Ki of
the complexes (Table 1). The meas-
uredKi value of SFTI-1 (0.03 nM) is
in good agreement with that
reported for SFTI-1 isolated from
sunflower seeds (0.1 nM (3)). Not
surprisingly, the P1 reactive site
mutant K5A is a considerably
weaker inhibitor (Ki 190 nM). All of
the mutants inhibit trypsin at low
nanomolar concentration, the Ki
values differing less than 50-fold
from that of SFTI-1.
DISCUSSION
SFTI-1 is one of the most potent
BBIs known and has exciting poten-
tial therapeutic applications based
on its inhibitory activity against
matriptase, an enzyme implicated in
FIGURE 4. Secondary shift analysis of SFTI-1 alanine mutants compared with native SFTI-1. The H sec-
ondary shifts were calculated by subtracting the random coil shift (40) from the H shift.
FIGURE 5. Comparison of the TOCSY spectra of native SFTI-1 and the D14Amutant. The spin systems are
labeled with the single letter amino acid code and residue number. SFTI-1 exists as a single well defined
conformation, whereas in D14A the Pro13 is present in both the cis and trans forms. The cis conformer of D14A
is highlighted with boxes.
Structural Analysis of SFTI-1
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prostate cancer (14). Furthermore, because of its tightly con-
strained structure, it has been suggested that it may serve as a
scaffold for peptide-based drug development (5, 27–29). In this
study, a suite of alaninemutants of SFTI-1 has been synthesized
to facilitate a determination of structure-activity relationships,
as such an analysis is critical if the therapeutic potential of the
SFTI-1 framework is to be realized.
We employed Boc chemistry and a thioester-based native
chemical ligation approach to cyclize the SFTI-1mutants. Such
an approach has been successfully applied to another family of
macrocyclic plant proteins, namely the cyclotides, which con-
tain three disulfide bonds and hence are intrinsically more
complex (9). The method worked efficiently for the suite of
SFTI-1 mutants, and in all but one case only a single step reac-
tion was required. The D14A mutant required a two-step pro-
cedure to facilitate cyclization and oxidation. Our approach
represents a novel and efficient method of synthesizing SFTI-1
analogues. In the past, several methods have been used to syn-
thesize SFTI-1 and analogues, including an on-resin cyclization
approach (4) and Fmoc (N-(9-fluorenyl)methoxycarbonyl)
chemistry followed by cyclization in solution (30). All have been
successful, thus emphasizing the synthetic accessibility of the
framework, but the thioester approach has the advantage of a
single step cyclization and oxidation reaction.
The similarity of theHchemical shifts between themutants
and native SFTI-1 suggests that no major structural changes
occur in the majority of the mutants. The most significant dif-
ferences from the native peptide are for mutants I7A, P8A, and
P9A, indicating that the Ile7–Pro9 region of the sequence is
important for structural integrity. These residues are in a turn
region of the binding loop adjacent to the active site Lys5–Ser6
peptide bond, and include the cis-Pro residue conserved in the
P3-position of all BBIs. The other significant mutation from a
structural perspective occurs in the secondary loop, where
mutation of Asp14 to an Ala destabilizes a turn region and leads
to cis-trans isomerization of Pro13.
The most significant loss in activity was observed in K5A.
The importance of the Lys is of course expected as it is the P1
residue and primarily responsible for recognition of the prote-
ase. However, the lack of importance of other residues is sur-
prising given that the conserved cis-proline at P3 has been
found to be also critical for function in studies of related pep-
tides. For instance, when the active sequence of SFTI-1 was
grafted onto a D-Pro-L-Pro template and each residue in the
binding loopwas subsequently replaced with alanine, both Lys5
and Pro8 were found to be critical for activity, with substitution
of Pro8 having a greater effect on activity than substitution of
Lys5 (31). The binding loop template used for those studies was
essentially a truncated SFTI-1molecule in which the secondary
loop is omitted, as illustrated in Fig. 6A. Pro8 of SFTI-1 is equiv-
alent to the cis-proline conserved throughout the known Bow-
man-Birk inhibitors, and so it is interesting that we find in this
study that it is not as crucial in maintaining activity in the full
SFTI-1 scaffold.
The discrepancy between the role of the cis-proline in the
truncated versus full SFTI-1 scaffold appears to be related to the
influence of the secondary loop on the structure of the binding
loop. Structure-activity studies of the proline residues in disul-
fide-cyclized peptides corresponding to BBI reactive site loops
(Fig. 6B) showed that replacement of the P3 Pro with Ala
resulted in poorly defined structure and poor inhibitory activity
(27). Furthermore, mutation of the Pro at the P4-position with
Ala resulted in cis-trans isomerization of the Pro at P3 (27). In
this study we have shown that mutation of the prolines at the
P3- and P4-positions of SFTI-1 (i.e. Pro8 and Pro9) does not
result in multiple conformations, and indeed Pro8 still adopts a
single well defined conformation with a cis-peptide bond in the
P9A mutant. Clearly, the full SFTI-1 scaffold stabilizes the
active conformation and can accommodate sequence varia-
tions to a greater extent than the disulfide-linked or D-Pro-L-
Pro capped binding loop sequences alone. In other words, the
secondary loop in SFTI-1 clearly plays an important role in
stabilizing the binding loop.
We explored the structural features of the secondary loop
that makes it a useful stabilizing template. Most residues are
relatively tolerant to substitution, but mutating Asp14 to Ala in
the secondary loop results in two distinct conformations that
differ by the presence of a cis- or trans-proline at position 13.
The conformations of the other two prolines are the same as in
the native peptide (i.e. Pro8 and Pro9 are in cis and trans con-
formations, respectively). As two sets of peaks are observed for
themajority of residues inD14A, the alternative conformations
are in slow exchange on the NMR time scale, consistent with
the energy barrier normally seen between cis- and trans-Pro
isomers in peptides. The stabilizing role of Asp14 appears to be
related to its ability to hydrogen-bond to the backbone of the
secondary loop. Specifically, in native SFTI-1 a hydrogen bond
is present between the side chain of Asp14 and the backbone
amide of Arg2 (4), as shown in Fig. 6C. In theD14Amutant, this
hydrogen bond is clearly not possible, and its absence most
likely accounts for the two distinct conformations observed.
The importance of the Asp14–Arg2 side chain to NH hydrogen
bond is reinforced by the fact that the Arg2 carbonyl group in
turn hydrogen-bonds to the backbone NH of Phe12. Thus, the
secondary loop has a well defined hydrogen bonding network
that helps establish it as a template for defining the structure of
the binding loop. This hydrogen bond network is schematically
illustrated in Fig. 6D.
As an aside, the presence of a Phe residue preceding Pro13
is likely to be an important factor influencing the presence of
TABLE 1
Equilibrium dissociation constant Ki for the inhibition of bovine
trypsin by SFTI-1 and its alanine mutants
Peptide Sequence Kia
nM
SFTI-1 -GRCTKSIPPICFPD- 0.03 0.01
G1A -ARCTKSIPPICFPD- 0.08 0.02
R2A -GACTKSIPPICFPD- 0.47 0.05
T4A -GRCAKSIPPICFPD- 0.26 0.05
K5A -GRCTASIPPICFPD- 190 39
S6A -GRCTKAIPPICFPD- 0.35 0.04
I7A -GRCTKSAPPICFPD- 0.84 0.25
P8A -GRCTKSIAPICFPD- 1.49 0.19
P9A -GRCTKSIPAICFPD- 0.08 0.04
I10A -GRCTKSIPPACFPD- 0.11 0.02
F12A -GRCTKSIPPICAPD- 0.53 0.06
P13A -GRCTKSIPPICFAD- 0.05 0.01
D14A -GRCTKSIPPICFPA- 0.24 0.05
a Values are mean S.D., n 4.
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cis and trans isomers in D14A, but the importance of the
Asp14–Arg2 hydrogen bond is re-emphasized by considering
the role of the Phe residue. Previous studies in a diverse
range of peptides have shown that
aromatic residues have a high pro-
pensity of favoring cis peptide
bond conformations when preced-
ing proline residues (32, 33). It is
interesting that the Phe12–Pro13
peptide bond in native SFTI-1 is
not in the cis conformation despite
the high propensity for such a con-
formation in model peptides, but
this may be explained by the influ-
ence of the Asp-Arg hydrogen
bond. Removal of the hydrogen
bond between Asp14 and Arg2
destabilizes this turn region and
allows measurable populations of
the more favorable cis conforma-
tion to be detected. Thus, the
tightly folded nature of SFTI-1
may have a greater influence on
the geometry of the proline resi-
dues than is normally observed in
model peptides. Overall, the stabi-
lizing hydrogen bond network
may be summarized as follows: the
Asp14 side chain hydrogen bonds
to the backbone NH of Arg2, facil-
itating orientation of its CO to
hydrogen bond to Phe12, which in
turn assists in maintaining a trans
conformation for Pro13, which in
turn orients Asp14, and the cycle
continues.
The role of Asp14 in maintaining
the structure of the cyclic scaffold is
intriguing given that this residue is
likely to be involved in the process-
ing reaction to form the native
cyclic peptide from its precursor
protein (8). How is it that a residue
implicated in cyclization, and hence
likely to change its conformation in
the transition from precursor to
mature cyclic peptide, can play such
an important structural role? One
could speculate that SFTI-1 is evo-
lutionarily related to an ancient pro-
tein encoding a BBI-like active site
domain that at some point acquired
a mutation leading to Asp at posi-
tion 14. This predisposed the mole-
cule to the potential for cyclization,
in part driven by the thermody-
namic stability that results when
Asp14 is able to hydrogen-bond to
the residue that in the cyclic molecule is only two residues
sequentially adjacent (Arg2) but is 12 residues away in sequence
in the linear version.
FIGURE6.SFTI-1variants thathavebeenused in structure-activity studies.A, truncatedderivative inwhich
a D-Pro-L-Pro template was used to display the binding loop (31). B, disulfide-cyclized peptide was used to
determine structure-activity relationships of the Pro residues of the reactive site loop of the BBIs. C, hydrogen
bonding of SFTI-1 involving Arg2 and Asp14. The hydrogen bond between the side chain of Asp14 and the
backbone of Arg2 is highlighted in ball and stick format. Pro13 is in a trans conformation in the native peptide
and retains this conformation in F12A but has two conformations in D14A. D, schematic illustration of the
hydrogen bonding network in SFTI-1.
Structural Analysis of SFTI-1
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With respect to speculation on processing mechanisms, it
is of interest to note that although it appears likely that Asp14
is indeed implicated in cyclization, this has not yet been
established with certainty, and consideration of the precur-
sor sequence of SFTI-1 alone still allows the possibility of
three alternative processing sites, involving cleavage before
or after Gly or Arg as illustrated in Fig. 1. A similar ambiguity
occurred originally for the cyclotides, where the presence of
GLP triplets flanking the mature peptide sequence led to
four potential cleavage sites (10, 34). The latter ambiguity
was resolved when consideration of numerous cyclotide
sequences showed that the first of the two GLP triplets is
incorporated into the mature peptide and that cleavage after
an Asn or Asp residue excises the second GLP from the
mature peptide during processing from the precursor (10,
35, 36). By analogy, in SFTI-1 it seems likely that the first GR
doublet is incorporated, and the second is excised because of
cleavage after Asp. However, SFTI-1 differs from the cycloti-
des in that only a single variant has been discovered so far,
whereas there are many cyclotide variants (37).
The proposal that Asp or Asn residues are likely involved
as C-terminal processing points in cyclization reactions is
supported by the common occurrence of asparaginyl
endopeptidases in plants. Presumably, such enzymes could
be recruited by linear precursor proteins to catalyze cycliza-
tion as a supplemental activity to their usual proteolytic
function. In the case of SFTI-1, we recently demonstrated
the principle of this “reverse” use of an enzyme by showing
that an acyclic permutant of SFTI-1 with the backbone bro-
ken at the Lys5–Ser6 peptide bond is able to be efficiently
cyclized by trypsin (38).
The lack of natural variants of SFTI-1 in sunflower seeds
or indeed other plants supports the notion that it has an
extremely optimized framework for trypsin inhibitory activ-
ity. This is in stark contrast to the plant cyclotides where
there are more than 80 published sequences and thousands
of predicted sequences (9, 39). This fundamental difference
between the two types of cyclic plant peptides is likely to be
related to their mechanisms of action. Cyclotides are insec-
ticidal agents and are thought to interact with membranes as
part of their mode of action (10). A nonspecific mode of
action perhaps lends itself to more sequence variation than
the highly specific nature of a protease inhibitor such as
SFTI-1.
In summary, despite the highly optimized framework of
SFTI-1, we have shown that it can accommodate sequence
variations and still allow the native-like fold to be main-
tained with significant levels of trypsin inhibitory activity.
This result is in contrast to previous studies on truncated
derivatives that only contain the binding loop of SFTI-1 (27,
31) and demonstrates that the secondary loop is a crucial
stabilizing factor in SFTI-1. In particular, Asp14 from the
secondary loop is a key residue in maintaining the well
defined native structure. As this residue is likely to be
involved in the cyclization process, its role in stabilizing the
cyclic scaffold may have implications for the evolution of
SFTI-1. This study has significantly broadened our under-
standing of the structure-activity relationships of SFTI-1,
and the finding that a flanking loop can play a crucial stabi-
lizing role provides important information for the design of
novel trypsin inhibitors in general.
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